$$$$$$$~BIG OTC DD PICKS AND LOW FLOAT MOVERS$$$$$$$

[flemsnopes]

$ACBFF Aurora Announces Q1 2017 Results

Canada NewsWire
VANCOUVER, Nov. 29, 2016 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced its financial and operational results for the quarter ended September 30, 2016.

Operational Highlights and Recent Developments Subsequent to Q1 2017

Aurora further strengthened its balance sheet with a current cash position of approximately $50 million, an increase since September 30, 2016 resulting from approximately $34 million in new equity and debt financings;
Announced plans to construct a new 600,000 square foot state-of-the-art facility (subsequently increased to at least 650,000 square foot), increasing total production capacity to more than 70,000 kg annually. Management believes the state-of-the-art nature of the new facility will contribute to significant savings in production costs on a per gram basis;
10,800 active registered patients as at November 28, 2016, reflecting what management believes is the fastest patient registration rate in the industry after commencement of commercial operations;
Achieved new sales milestones:
Continued sales pace in excess of $1 million per month
November, 2016 on track to be record month, with product sales projected in excess of 200 kilograms and gross revenue in excess of $1.6 million
Achieved a seven-day sales record between November 18 and 24, 2016, with more than 62 kilograms sold over that period
Aurora well positioned for the future with approximately $30 million in additional gross cash proceeds remain available from remaining warrants, stock options and compensation options/warrants;
Converted $15 million of 10% convertible debentures into common shares.
Migrated listing from CSE to TSX-V, which the Company anticipates will increase liquidity and its potential investor audience;
Further strengthened board governance with the appointment of Michael Singer as Chairman of the board and the appointment of Joseph Del Moral and Barry Fishman as members of the board;
Appointed Cam Battley as Executive Vice President;
Began establishment of onsite analytical laboratory, to accelerate product time to market and increase sales capacity;
CanvasRx currently exceeds 13,000 registered patients, including more than 2,500 patients registered with Aurora as of today, representing a growth in patient registration in excess of 30% since being acquired by Aurora;
http://www.otcmarkets.com/stock/ACBFF/news/Aurora-Announces-Q1-2017-Results?id=145926&b=y